Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CHICAGO, Jan. 03, 2017 -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced Sean Nolan, President and Chief Executive Officer, will present a corporate update at the 35th Annual J.P. Morgan Healthcare Conference at 5:00 p.m. PST, Monday, January 9, 2017, with a Q&A session to follow.
A live, listen-only webcast of the presentation will be accessible on the Events and Presentations page within the Investors and Media section of the AveXis website at www.AveXis.com. A replay of the presentation will be available at the same location for 30 days following the conference.
About SMA
SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births. SMA is the leading genetic cause of infant mortality.
The most severe form of SMA is Type 1, a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. Approximately 30 percent of cases are expected to be SMA Type 2. SMA Type 2 typically presents between six and 18 months of age. Affected patients will never walk without support, and SMA Type 2 results in mortality for more than 30 percent of patients by age 25.
About AVXS-101
AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Type 1 and is designed to address the monogenic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN1 gene. AVXS-101 also targets motor neurons providing rapid onset of effect, and crosses the blood brain barrier allowing an IV dosing route and effective targeting of both central and systemic features.
About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.
Media Inquiries: Lauren Barbiero W2O Group 646-564-2156 [email protected] Investor Inquiries: Jim Goff AveXis, Inc. 650-862-4134 [email protected]
